Compare QUALCOMM, Inc. (QCOM) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
QUALCOMM, Inc. vs Summit Therapeutics Inc — how do they compare? QUALCOMM, Inc. trades at $176.22 (market cap $182.87B), while Summit Therapeutics Inc trades at $14.78 (market cap $11.34B). The key difference: QUALCOMM, Inc. is far larger — about 16.1× Summit Therapeutics Inc's market cap, and QUALCOMM, Inc. pays a 2.12% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| QCOM | SMMT | |
|---|---|---|
Market Cap | $182.87B | $11.34B |
Sector | Technology | Health |
52-Week High | $251.10 | $29.32 |
52-Week Low | $124.07 | $13.05 |
Enterprise Value | $188.34B | $10.76B |
Dividend Yield | 2.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Qualcomm (QCOM) trades at $175.55, up 3.07% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 22.31% net income margin and 29.27% ROE, though margins face pressure. Analyst consensus is a $228.22 price target with 42.65% buy ratings. Recent news highlights AI and data center growth initiatives amid smartphone market challenges.
The outlook balances AI diversification potential against near-term margin and competitive risks. Investment opportunity lies in data center revenue growth and market share gains, but risks include Nvidia's PC chip entry and handset demand softness. Wall Street remains cautiously optimistic with a hold-heavy rating distribution.
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.
The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
